Organoid-on-a-Chip Technology to Accelerate Predictive Drug Development
ABOUT US
Single-Cell Microfluidics and Advanced Technologies
Acoustic Bio is pioneering technologies that automate and scale the screening of patient-derived organoids (PDOs) for drug development. By integrating microfluidics, live imaging, acoustic technology, and machine vision, we have developed an innovative and high-throughput solution for organoid screening. Our approach enhances the predictivity of organoid screening, enabling the development of drugs with greater likelihood of success in patients.
Miniaturization
High-Throughput Discovery
Patented Acoustic Technology
SIMPLIFY WORKFLOWS with
integrated system
Miniaturization, automation, and real-time imaging enables high-throughput assays on a microfluidic chip
PIONEERING SOLUTIONS
Extensive
Application Potential
Preclinical Drug Development
High-throughput screening assays for lead identification using patient-derived organoids as predictive disease model
Personalized Medicine
Predict stratification of patients into clinical trials and identify which drugs are most effective for specific patient populations
Biomarker Discovery
Identify biomarkers that are associated with drug response by phenotypic and multi-omics analysis of organoids
Immunotherapy
Co-culture tumor organoids with engineered immune cells to monitor their interactions, such as cytotoxic potential
How it works
A powerful platform for high-throughput screening of patient-derived organoids
INNOVATION IN ACTION
Retrieval for multi-omics analysis
Real-time video of acoustic retrieval of brain organoid
Acoustic Bio
MEET THE TEAM
We are a group of technologists working at the intersections of engineering and biology to build a novel platform to accelerate single-cell analysis. The team has extensive experience in commercialization of microfluidic imaging systems.
TEAM MEMBERS
Bahram Fathollahi, PhD Founder & CEO
- 20+ years R&D leader in commercialization of Microfluidic Platforms, established partnership with pharma on technology adoption
- Grew revenue from $25M to $150M. Caliper acquired by PerkinElmer for $750M
Dan Stearns, PhD Founder & CTO
- 25+ years R&D leader in commercialization of Biological Imaging Systems
- Xenogen acquired by Caliper Lifesciences for $80M
Jay WhalenDirector of Engineering
David PeisleySenior Systems Engineer
SCIENTIFIC ADVISORS
Join US
Career
Opportunities
Contact Us
We are open to explore strategic partnerships on the use of our platform for novel bioproduct discovery